WO2006059111A3 - Fungal signalling and metabolic enzymes - Google Patents

Fungal signalling and metabolic enzymes Download PDF

Info

Publication number
WO2006059111A3
WO2006059111A3 PCT/GB2005/004604 GB2005004604W WO2006059111A3 WO 2006059111 A3 WO2006059111 A3 WO 2006059111A3 GB 2005004604 W GB2005004604 W GB 2005004604W WO 2006059111 A3 WO2006059111 A3 WO 2006059111A3
Authority
WO
WIPO (PCT)
Prior art keywords
iii
protein
fungal
sequence
signalling
Prior art date
Application number
PCT/GB2005/004604
Other languages
French (fr)
Other versions
WO2006059111A2 (en
Inventor
Nina Brogden
Michael John Bromley
Paul David Carr
Sarah Jane Kaye
Jason David Oliver
Daniel Scott Tuckwell
Original Assignee
F2G Ltd
Nina Brogden
Michael John Bromley
Paul David Carr
Sarah Jane Kaye
Jason David Oliver
Daniel Scott Tuckwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426390A external-priority patent/GB0426390D0/en
Priority claimed from GB0521062A external-priority patent/GB0521062D0/en
Application filed by F2G Ltd, Nina Brogden, Michael John Bromley, Paul David Carr, Sarah Jane Kaye, Jason David Oliver, Daniel Scott Tuckwell filed Critical F2G Ltd
Priority to US11/720,664 priority Critical patent/US20110081348A1/en
Priority to EP05811554A priority patent/EP1825272A2/en
Priority to JP2007543913A priority patent/JP2008521427A/en
Publication of WO2006059111A2 publication Critical patent/WO2006059111A2/en
Publication of WO2006059111A3 publication Critical patent/WO2006059111A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Method of identifying an anti-fungal agent which targets as an essential protein or gene of a fungus comprising contacting a candidate substance with (i) a protein which comprises the sequence shown by SEQ ID NOS: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 50, 53, 56, 59, 61 or 63, or (ii) a protein which has 60% identity with (i), or (iii) a protein comprising a fragment of (i) or (ii) which fragment has a length of at least 50 amino acids, or (iv) a polynucleotide that comprises a sequence which encodes (i), (ii) or (iii), or (v) a polynucleotide comprising a sequence which has at least 70% identity with the coding sequence of (iv), and determining whether the candidate substance binds or modulates (i), (ii), (iii), (iv), or (v), wherein binding or modulation of (i), (ii), (iii), (iv), or (v) indicates that the candidate substance is an anti-fungal agent.
PCT/GB2005/004604 2004-12-01 2005-12-01 Fungal signalling and metabolic enzymes WO2006059111A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/720,664 US20110081348A1 (en) 2004-12-01 2005-12-01 Fungal signalling and metabolic enzymes
EP05811554A EP1825272A2 (en) 2004-12-01 2005-12-01 Fungal signalling and metabolic enzymes
JP2007543913A JP2008521427A (en) 2004-12-01 2005-12-01 Fungal signaling and metabolic enzymes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0426390.1 2004-12-01
GB0426390A GB0426390D0 (en) 2004-12-01 2004-12-01 Fungal signalling and metabolic enzymes
GB0521062.0 2005-10-17
GB0521062A GB0521062D0 (en) 2005-10-17 2005-10-17 Fungal signalling and metabolic enzymes

Publications (2)

Publication Number Publication Date
WO2006059111A2 WO2006059111A2 (en) 2006-06-08
WO2006059111A3 true WO2006059111A3 (en) 2006-08-31

Family

ID=35883555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004604 WO2006059111A2 (en) 2004-12-01 2005-12-01 Fungal signalling and metabolic enzymes

Country Status (4)

Country Link
US (1) US20110081348A1 (en)
EP (1) EP1825272A2 (en)
JP (1) JP2008521427A (en)
WO (1) WO2006059111A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297016B2 (en) 2010-02-17 2016-03-29 Butamax Advanced Biofuels Llc Activity of Fe—S cluster requiring proteins
US9580705B2 (en) 2013-03-15 2017-02-28 Butamax Advanced Biofuels Llc DHAD variants and methods of screening

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133141A1 (en) * 2007-04-24 2008-11-06 Toyo Boseki Kabushiki Kaisha Osmotin recombinant protein, method for production of the same, and use of the same
NZ591244A (en) 2008-09-29 2013-03-28 Butamax Tm Advanced Biofuels IDENTIFICATION AND USE OF BACTERIAL [2Fe-2S] DIHYDROXY-ACID DEHYDRATASES
BRPI0913552B1 (en) 2008-09-29 2020-09-29 Butamax Advanced Biofuels Llc METHOD FOR PRODUCTION OF ISOBUTANOL AND METHOD FOR CONVERSION OF 2,3-DIHYDROXY ISOVALERATE
WO2011019894A1 (en) * 2009-08-12 2011-02-17 Gevo, Inc. Cytosolic isobutanol pathway localization for the production of isobutanol
MY156003A (en) 2009-11-24 2015-12-31 Gevo Inc Methods of increasing dihydroxy acid dehydratase activity to improve production of fuels, chemicals, and amino acids
WO2014106107A2 (en) 2012-12-28 2014-07-03 Butamax (Tm) Advanced Biofuels Llc Dhad variants for butanol production
WO2018189502A1 (en) * 2017-04-12 2018-10-18 Momentum Bioscience Limited Detection and delineation of microorganisms using the ilv3 gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998420A (en) * 1996-04-08 1999-12-07 University Of Medicine & Dentistry Of New Jersey Method for treating Mycobacterium tuberculosis
US6465198B1 (en) * 1997-11-07 2002-10-15 Millennium Pharmaceuticals, Inc. Essential fungal genes and their use
DE10261834A1 (en) * 2002-12-20 2004-07-08 Phenion Gmbh & Co. Kg High-throughput suitable screening process for the identification of active substances

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998420A (en) * 1996-04-08 1999-12-07 University Of Medicine & Dentistry Of New Jersey Method for treating Mycobacterium tuberculosis
US6465198B1 (en) * 1997-11-07 2002-10-15 Millennium Pharmaceuticals, Inc. Essential fungal genes and their use
DE10261834A1 (en) * 2002-12-20 2004-07-08 Phenion Gmbh & Co. Kg High-throughput suitable screening process for the identification of active substances

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WESTKAEMPER R B ET AL: "SYNTHESIS AND EVALUATION OF 1 HYDROXYCYCLOPROPANECARBOXYLIC ACIDS AS POTENTIAL TRANSITION STATE INHIBITORS OF DIHYDROXY-ACID DEHYDRATASE", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 23, no. 3, 1988, pages 233 - 236, XP002370533, ISSN: 0223-5234 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9297016B2 (en) 2010-02-17 2016-03-29 Butamax Advanced Biofuels Llc Activity of Fe—S cluster requiring proteins
US9580705B2 (en) 2013-03-15 2017-02-28 Butamax Advanced Biofuels Llc DHAD variants and methods of screening

Also Published As

Publication number Publication date
EP1825272A2 (en) 2007-08-29
WO2006059111A2 (en) 2006-06-08
US20110081348A1 (en) 2011-04-07
JP2008521427A (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2006059111A3 (en) Fungal signalling and metabolic enzymes
NZ595499A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
WO2004048592A3 (en) Bgl7 beta-glucosidase and nucleic acids encoding the same
WO2003081210A3 (en) Identification of kinase inhibitors
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2005087811A3 (en) Estrogen receptors and methods of use
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
WO2001036641A3 (en) DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO
WO2003076949A3 (en) Tagging and recovery of elements associated with target molecules
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
WO2009086125A3 (en) Affinity tag nucleic acid and protein compositions, and processes for using same
WO2004033485A3 (en) Nucleic acid supported protein complementation
WO2005080588A3 (en) 2031 oxidoreductase
WO2005095975A3 (en) Anti-fungal target genes
WO2007014951A3 (en) Methods for the screening of antibacterial substances
WO2001066752A3 (en) Reproduction-specific genes
WO2003020887A3 (en) Gene identification
WO2005034840A3 (en) Identification of kinase inhibitors
WO2006097564A3 (en) Novel soluble epcr protein of non-proteolytic origin and use thereof
WO2003038116A3 (en) Salmonella virulence factors and uses thereof
TW200604207A (en) A superantigen fusion protein and the use thereof
WO2005080420A3 (en) Hyphal growth in fungi
WO2009083968A8 (en) Novel protein
WO2003094844A3 (en) Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms
WO2008038272A3 (en) Isolated polynucleotides, nucleic acid constructs, methods and kits for localization of rna and/or polypeptides within living cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007543913

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005811554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005811554

Country of ref document: EP